How do TFs and #chromatin remodeling work together to drive cancer? Are pioneer TFs real? How does SWI/SNF (BAF) inhibition influence normal immune cells? Are all #AML tumors responsive? Check out the latest paper by Courtney Chambers aacrjournals.org/cancerres/arti…

Courtney Chambers We found that binding of the pioneer TF PU.1 to its target enhancers is independent of SWI/SNF activity in AML cells. But PU.1 recruits SWI/SNF to generate DNA accessibility for other members of the AML core regulatory circuitry

Dr. H.C. Hodges H. Courtney Hodges, C Chambers Courtney Chambers, Drs. Rachel Rau, K Cermakova Katerina Cermakova, cermakova.bsky.social et al reveal an #epigenetic vulnerability of #acuteMyeloidLeukemia Cancer Research Dan L Duncan Comprehensive Cancer Center BCMHouston BCM Graduate School of Biomedical Sciences #SWISNF #PU1 bcm.edu/news/study-rev…

Thrilled to share Peggy Goodell’s latest work on a new role for DNMT3A in stem cell activation via coordination of RNA splicing in @naturecellbio nature.com/articles/s4155… 🧵below (and read here: rdcu.be/c9kFF)

On April 12, 1980, Terry Fox began his Marathon of Hope. Nearly 43 years later, researchers like Dr. Sumit Gupta The Hospital for Sick Children (SickKids) are continuing Terry's marathon, inspired by his dream of a world without cancer. Learn more about Dr. Gupta's work ▶️ bit.ly/3MDA9Ng

Maxim MaximPimkin , MD, PhD discusses "Gene regulatory networks in leukemia maintenance and immune escape." in our CAGT Seminar Series. What are your theories? #research

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL BCMHouston Society of Hematologic Oncology (SOHO) #SOHO2024 #SOHO24 #leusm onclive.com/view/tisagenle…

Presented at #ASH24: The addition of blinatumomab after induction chemotherapy in children with standard-risk disease of average or high risk of relapse significantly improved disease-free survival. Full AALL1731 trial results: nej.md/49CVkc1

B-ALL NEWS: Today, Amgen announced that Children’s Oncology Group will present study results for pediatric patients with B-cell precursor acute lymphoblastic leukemia (B-ALL) at ASH’s annual meeting, #ASH24. 🔗 Press release: amgen.ly/4g2K7Uq

#ASH24 attendees! Don’t miss Rachel Rau presenting research that’s shaping the standard of care for pediatric #leukemia. Learn more at today’s Plenary Scientific Session about this study out of Seattle Children's, The Hospital for Sick Children (SickKids) and Children’s Oncology Group

We congratulate the #COG institutions who took part in #AALL1731, as well as Amgen 🧪🔬🧬, the maker of BLINCYTO®. A special congratulations to Drs. Rachel Rau & Gupta, for co-chairing this transformative study. Lastly, thank you to all of the patients & families who participated.

🔬 Exciting pediatric leukemia breakthrough! A new study is helping boost survival rates for kids with B-ALL #leukemia. Learn more about this research, co-led by Rachel Rau, under the leadership of Dr. Mignon Loh, from Seattle Children's, The Hospital for Sick Children (SickKids), and Children’s Oncology Group:

Joy is everywhere at #ASH24 🩸 It's in the exchange of ideas — from session rooms to dinner conversations — in the reunions we cherish each year, and in celebrating our colleagues' incredible achievements. Every moment feels special and fun, and some are unexpected! 🐶🦄

Over 15 #COG authors presented at ASH #ASH24 this weekend, including #AALL1731 study co-chairs Drs. Rau and Gupta at the plenary session! Congratulations to all the authors on their presentations!

A B-cell acute lymphoblastic leukemia clinical trial, "...Showed a stunning improvement in the rate of three-year disease-free survival of patients from around 87% to around 96%. It was beyond anyone’s expectations," said Rachel Rau, MD, Seattle Children's. seattlechildrens.org/research/featu…